Group 1 - The core viewpoint of the news is that institutional investors hold a significant portion of Weili Medical's shares, with a total of 1.62 billion shares, accounting for 55.24% of the total share capital as of October 20, 2025 [1] - The proportion of shares held by institutional investors increased by 0.15 percentage points compared to the previous quarter [1] - Among public funds, only one fund, the China Merchants Quantitative Selected Stock Initiation A, increased its holdings, with an increase of 0.24% [1] Group 2 - The National Social Security Fund's 412 portfolio is the only social security fund that increased its holdings, with an increase of 0.25% [2] - Two new insurance investors were disclosed this quarter, both from Taikang Life Insurance, indicating a growing interest from insurance capital [2] - Two pension funds were not disclosed in this quarter compared to the previous one, reflecting a potential shift in investment strategy [2]

Core Insights - The company reported a revenue of 446 million yuan for the third quarter, representing a year-on-year growth of 16.09% [1] - The net profit for the same period was 70.57 million yuan, showing a year-on-year increase of 16.31% [1] - For the first three quarters of 2025, the total operating revenue reached 1.191 billion yuan, with a year-on-year growth of 12.33% [1] - The net profit for the first three quarters was 192 million yuan, reflecting a year-on-year increase of 14.94% [1] - The basic earnings per share for the period was 0.65 yuan [1]

Core Viewpoint - A total of 80 stocks have shown a continuous improvement in net profit for two consecutive quarters, indicating a positive trend in profitability [1] Group 1: Profitability Trends - As of the third quarter of 2025, 80 stocks have reported profitability with both the third and second quarters showing sequential net profit growth [1] - Continuous improvement in net profit suggests that these companies are in a phase of sustained profitability enhancement [1] Group 2: Valuation Levels - Among the 80 stocks with improving performance, 29 have a rolling price-to-earnings (PE) ratio below 30 times [1] - Xinhua Insurance has the lowest rolling PE ratio at 7.01 times, while several companies like Zijin Mining, Hanhua Environment, and others have PE ratios ranging from 10 to 20 times [1] Group 3: Capital Inflows - Recently, some low PE ratio stocks with continuous performance improvement have attracted increased investment from financing clients [1] - As of October 20, 2023, seven stocks have seen net financing purchases exceeding 100 million yuan since October, with Zijin Mining leading at a net purchase of 2.349 billion yuan [1]

Core Points - Vili Medical's stock increased by 5.04% to 14.17 CNY per share, with a trading volume of 51.81 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 4.15 billion CNY [1] - The company, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Vili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Vili Medical, with the Xinda Small and Medium Cap Mixed A Fund (610004) reducing its stake by 69.96 thousand shares in the second quarter, now holding 77.05 thousand shares, which represents 4.54% of the fund's net value [2] - The fund has achieved a floating profit of approximately 523.9 thousand CNY as of the latest report [2] - The Xinda Small and Medium Cap Mixed A Fund was established on December 1, 2009, with a current size of 216 million CNY, and has recorded a year-to-date return of 24.01% [2] Fund Management - The fund is managed by Zeng Guofu and Li Diandian, with Zeng having a tenure of 17 years and 88 days, overseeing assets totaling 481 million CNY, achieving a best return of 109.1% during his tenure [3] - Li Diandian has been managing the fund for 1 year and 7 days, with assets of 570 million CNY, and has achieved a best return of 35.83% during his management period [3]

Core Insights - The company reported a total revenue of 1.191 billion yuan for Q3 2025, with a net profit attributable to shareholders of 192 million yuan [1] - The operating cash flow showed a net inflow of 160 million yuan [1] - The asset-liability ratio increased to 33.03%, up by 0.69 percentage points compared to the same period last year [1] Financial Performance - The latest gross profit margin is 44.18%, which is a decrease of 0.86 percentage points from the previous quarter and a decrease of 0.62 percentage points from the same period last year [1] - The return on equity (ROE) stands at 9.90% [1] - The diluted earnings per share (EPS) is 0.65 yuan [1] Operational Efficiency - The total asset turnover ratio is 0.41 times [1] - The inventory turnover ratio is 3.65 times [1] Shareholder Structure - The number of shareholders is 18,900, with the top ten shareholders holding a total of 165 million shares, accounting for 56.31% of the total share capital [1] - The largest shareholder is Gao Bo Investment (Hong Kong) Limited, holding 31.4 million shares [1] - Other significant shareholders include Guangzhou Songwei Enterprise Management Consulting Co., Ltd. and Guangzhou Weiyue Trade Consulting Co., Ltd. with holdings of 13.3 million and 5.35 million shares respectively [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603309 证券简称：维力医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二）非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 （三）主要会计数据、 ...

其中，公司第三季度营业收入4.46亿元，同比增长16.09%；归属净利润7056.6万元，同比增长16.31%。 北京商报讯（记者 丁宁）10月20日晚间，维力医疗（603309）发布2025年三季报显示，公司前三季度 实现营业收入11.91亿元，同比增长12.33%；归属净利润1.92亿元，同比增长14.94%。 ...

证券日报网讯 10月20日晚间，维力医疗发布2025年第三季度报告称，2025年第三季度公司实现营业收 入446，011，096.01元，同比增长16.09%；归属于上市公司股东的净利润为70，565，993.50元，同比 增长16.31%。 （文章来源：证券日报） ...

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

智通财经APP讯，维力医疗(603309.SH)披露2025年第三季度报告，公司前三季度实现营收11.91亿元， 同比增长12.33%;归属于上市公司股东的净利润1.92亿元，同比增长14.94%;扣非净利润1.84亿元，同比 增长15.22%;基本每股收益0.65元。 ...